Table 3.
Statistically significant correlations between the 8 monocyte surface antigens under study, for the particular subgroups
| Endometrial Cancer (N = 42) | Cervical Cancer (N = 13) | Ovarian Cancer (N = 14) | Group I (N = 20) | Group II (N = 23) |
|---|---|---|---|---|
| CD11a vs. CD54 (r = 0.444920; p = 0.0032) | (−) | CD11a vs. CD54 (r = 0.606311; p = 0.0216) | (−) | (−) |
| CD11b vs. CD64 (r = 0.390416; p = 0.0106) | CD11b vs. CD64 (r = 0.556329; p = 0.0484) | (−) | (−) | CD11b vs. CD64 (r = 0.534304; p = 0.0087) |
| (−) | CD11b vs. CD62 L (r = 0.789189; p = 0.0014) | (−) | (−) | (−) |
| (−) | CD11c vs. CD64 (r = − 0.645134; p = 0.0173) | (−) | (−) | (−) |
| (−) | CD11c vs. HLA-DR (r = 0.672398; p = 0.0119) | (−) | CD11c vs. HLA-DR (r = 0.445866; p = 0.0488) | (−) |
| (−) | (−) | CD16 vs. CD62 L (r = 0.554456; p = 0.0397) | (−) | (−) |
| (−) | (−) | (−) | (−) | CD16 vs. HLA-DR (r = − 0.506677; p = 0.0137) |
| CD54 vs. CD62 L (r = 0.518139; p = 0.0005) | CD54 vs. CD62 L (r = 0.570250; p = 0.0419) | CD54 vs. CD62 L (r = 0.550661; p = 0.0413) | (−) | CD54 vs. CD62 L (r = 0.426489; p = 0.0425) |
| (−) | (−) | (−) | CD54 vs. HLA-DR (r = −0.476692; p = 0.0336) | (−) |
Group I - women operated but had no malignancy in postoperative histopathologic examination, Group II - healthy women. r - Spearman correlation coefficient.